A single-arm open-label phase 2 study evaluating the efficacy and safety of abemaciclib in patients with recurrent oligodendroglioma

Recruiting
99 years or below
All
Phase 2
15 participants needed

Brief description of study

This is a single-center, phase II, single-arm, open label study evaluating the efficacy and safety of abemaciclib for patients with recurrent oligodendroglioma (molecularly defined per the WHO 2016 guidance, i.e., presence of IDH mutation and 1p19q codeletion). The study will enroll 10 subjects who are evaluable for the studys primary endpoint (subjects must be receive at least one dose of abemacicilb to be evaluable for the primary endpoint). The study will be stratified by number of lines of prior alkylating chemotherapy (one prior line versus two or more prior lines). Eligibility criteria are such that of the 10 total subjects enrolled, at least 2 must have had only one prior line of alkylating chemotherapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Oligodendroglioma, Adult
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 832198

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.